| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
218,516 |
203,758 |
$13.53M |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
146,208 |
132,005 |
$10.82M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
115,736 |
111,543 |
$6.40M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
74,478 |
67,733 |
$3.29M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
84,000 |
79,828 |
$2.12M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
26,477 |
25,350 |
$1.88M |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
24,585 |
22,479 |
$793K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
41,370 |
19,613 |
$381K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
37,602 |
35,550 |
$287K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
3,786 |
3,672 |
$178K |
| 99215 |
Prolong outpt/office vis |
1,888 |
1,836 |
$136K |
| 87428 |
|
10,607 |
8,756 |
$132K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,563 |
2,439 |
$80K |
| 81025 |
|
10,926 |
10,417 |
$40K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
6,042 |
5,627 |
$39K |
| 81002 |
|
24,342 |
23,149 |
$34K |
| 86328 |
|
894 |
838 |
$16K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,934 |
1,831 |
$9K |
| 99205 |
Prolong outpt/office vis |
55 |
49 |
$5K |
| A4250 |
Urine test or reagent strips or tablets (100 tablets or strips) |
23,189 |
22,070 |
$4K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
45 |
40 |
$3K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,860 |
1,752 |
$3K |
| 94664 |
|
646 |
590 |
$2K |
| 69210 |
|
137 |
129 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
133 |
127 |
$1K |
| 81001 |
|
1,396 |
1,369 |
$960.40 |
| 90686 |
|
71 |
64 |
$770.69 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,047 |
993 |
$557.81 |
| 99201 |
|
14 |
14 |
$538.40 |
| 87070 |
|
102 |
83 |
$511.43 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
70 |
64 |
$340.20 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
677 |
647 |
$284.76 |
| 94060 |
|
29 |
25 |
$211.04 |
| A6449 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard |
420 |
413 |
$179.71 |
| 73610 |
|
13 |
13 |
$126.47 |
| 86308 |
|
14 |
12 |
$63.96 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
1,645 |
1,548 |
$38.83 |
| 99000 |
|
6,592 |
6,289 |
$27.88 |
| 94760 |
|
2,856 |
2,661 |
$4.12 |
| A4550 |
Surgical trays |
13 |
12 |
$0.00 |
| 3511F |
|
13 |
13 |
$0.00 |
| H0033 |
Oral medication administration, direct observation |
18 |
17 |
$0.00 |